Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Pamidronate × Clear all
NCT00033332 2014-04-04

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00376883 2007-01-04

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Nordic Myeloma Study Group

Phase 3 Completed
500 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡